Navigation Links
NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference
Date:4/25/2013

AMES, Iowa, April 25, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that Nicholas N. Vahanian , M.D., NewLink's Chief Medical Officer, is scheduled to present at the Needham and Company 12th Annual Healthcare Conference in New York on Tuesday, April 30, 2013 at 12:50 p.m. ET.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for cancer patients.  NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications.  NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens.  NewLink's lead product candidate, algenpantucel-L (HyperAcute® Pancreas) is being studied in a Phase 3 clinical trial in surgically resected pancreatic cancer patients (under a Special Protocol Assessment with the U.S. FDA) as well as in a separate study in locally advanced pancreatic cancer patients.  NewLink has recently launched an adaptive design Phase 2B/3 clinical trial of tergenpumatucel-L (HyperAcute® Lung) in patients with non-small cell lung cancer.  NewLink is developing indoximod, a small molecule, orally bioavailable product candidate from NewLink's proprietary indoleamine-(2,3)-dioxygenase, or IDO, pathway inhibitor technology.  NewLink is studying indoximod in various chemotherapy and immunotherapy combination studies independently and in collaboration with the National Cancer Institute.  For more information please visit http://www.linkp.com.  Patient information is available at http://www.pancreaticcancer-clinicaltrials.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "target", "potential", "will", "could", "should", "seek", or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: the prospects of algenpantucel-L, indoximod and our other HyperAcute product candidates and related clinical trials. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including risks relating to: the initiation of clinical trials and the completion of enrollment; adverse general economic and industry conditions; and those risks discussed in "Risk Factors" and elsewhere in NewLink's Annual Report on Form 10-K for the period ended December 31, 2012, Form S-3 Registration Statement filed December 28, 2012 and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release represent NewLink's views as of the date of this press release. NewLink anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink's views as of any date subsequent to the date of this press release.

Contact:

Gordon Link 
Chief Financial Officer 
515-598-2925  
glink@linkp.com 


'/>"/>
SOURCE NewLink Genetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lota S. Zoth joins NewLinks Board of Directors; heads Audit Committee
2. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
3. NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock
4. NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock
5. NewLink Genetics Corporation Announces Exercise of Underwriters Option and Closing of Public Offering of Common Stock
6. NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call
7. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
8. Intermountain Healthcare and Myriad Genetics Enter Into Research Collaboration Agreement
9. Genelex Receives First Patent on Business Methods for Pharmacogenetics
10. Response Genetics, Inc. to Release Second Quarter Financial Results and Host Conference Call on August 14, 2012
11. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016  Nevro Corp. (NYSE: NVRO ), ... evidence-based solutions for the treatment of chronic pain, today ... has filed a lawsuit for patent infringement.  The lawsuit, ... District of Delaware , alleges that ... to stimulation leads, batteries, and telemetry units. ...
(Date:12/9/2016)... -- MSD, a nationally recognized supplier of technology enabled ... health care facilities, announced today that it has completed ... a privately held national distributor of medical supplies and ... segments. We would like to welcome First Choice to ... will deliver significant and immediate value to MSD,s customers ...
(Date:12/9/2016)... -- External Defibrillators, Implantable Cardioverter Defibrillators, ... Cardiac Resynchronization Therapy Defibrillators (CRT-D), Manual External Defibrillators, ... The global defibrillators market is expected ... 2016-2020 and CAGR of 5.1% from 2020-2026. The ... of 5.2% from 2016 to 2026. The market ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... The ... Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits and ... the District of Columbia as an education tool in the war against teen drug ...
(Date:12/9/2016)... ... 2016 , ... Mediaplanet today announces distribution of the latest edition of “Transplants,” ... up as an organ donor for the 123,000 people in the United States who ... save up to 8 saves through organ donation and enhance many others through tissue ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use ... nebulizer had a more child-friendly design, then children would be more likely to look ... to avoid the need to deliver medication via a nebulizer mask. The design will ...
(Date:12/8/2016)... Tampa, FL (PRWEB) , ... December 08, 2016 ... ... been awarded accreditation with distinction by the Undersea and Hyperbaric Medical Society (UHMS), ... patients with advanced care and patient safety. Only a few hospitals and facilities ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
Breaking Medicine News(10 mins):